Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Scientists at University of Maryland target breast cancer
May 22nd, 2008
"The ErbB3 binding protein ( Ebp1) is a transcriptional corepressor that inhibits the activity of proliferation- associated genes and the growth of human breast cancer cell lines. Treatment of breast cancer cells with the ErbB3 ligand heregulin ( HRG) results in increased phosphorylation of Ebp1 and transcriptional repression," researchers in the United States report. "The p21- activated serine/ threonine kinase 1 ( PAK1), which plays an important role in breast cancer progression and resistance to the anti- oestrogen tamoxifen, is also activated by HRG. We therefore examined the ability of PAK1 to phosphorylate and regulate the function of Ebp1. We found that PAK1...
Source: Women's Health Weekly (2008-05-22)
|
